Collectively, these findings identify RIPK1 as a critical driver of glioma malignancy and underscore the therapeutic potential of activating necroptosis to augment TMZ efficacy, providing a framework for novel prognostic and treatment strategies in glioma. This evidence concerns the gene RIPK1 and glioma.